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Background: Despite a superior hemodynamic profile, the clinical effectiveness of stentless porcine subcoronary aortic prostheses remains 
unclear.
Methods: A contemporary (1998-2007) cohort of 64,739 patients aged 65 years or older undergoing aortic valve replacement (AVR) with a 
stentless porcine (n=6,664) or stented bovine pericardial bioprosthesis (n=58,075) was identified at 1,261 centers participating in the STS Adult 
Cardiac Surgery datatabase. Clinical data were linked to Medicare data to permit up to 10 years of longitudinal follow-up of outcomes (mean 
5.4 years). Temporal trends in the use of stentless prostheses were evaluated. Mortality and morbidity events were examined after adjusting for 
treatment propensity using inverse probability weighted estimates.
Results: The use of stentless valves peaked in 2000 at 12.1% of all bioprostheses, and subsequently declined to 4.3% by 2007. In the Medicare-
linked cohort (median age, 77yrs; female, 42%), the 10-year unadjusted incidence of death (56.2% vs 63.3%) and rehospitalization for heart failure 
(24.6% vs 26.3%) was lower among those receiving stentless versus stented valves . The incidence of aortic valve reoperation (2.8% vs 2.4%), stroke 
(13.8% vs 12.3%), and endocarditis (1.4% vs 1.3%) was similar for stentless vs stented valves. Following risk-adjustment, stentless valves were 
associated with a statistically similar 10-year relative risk of mortality (HR 1.04; 95% CI 0.99, 1.10), rehospitalization for heart failure (HR 1.05; 
0.96, 1.14), aortic valve reoperation (HR 0.99; 0.73, 1.35), stroke (HR 1.09; 0.98, 1.21), and endocarditis (HR 0.82; 0.59, 1.14) compared with 
pericardial prostheses. 
Conclusions: By ten year follow-up, stentless porcine and stented pericardial AVR had similar adjusted risks for mortality or major morbidity when 
used in elderly patients. These data do not support the superiority of stentless aortic valve bioprostheses in elderly patients.
